Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,119.00-2.78%ETH$2,566.68-4.87%GOLD$4,134.20-0.16%OIL$88.79+0.58%
Smart Investors Daily
SID Premium
CG

NASDAQ · CGEN

Compugen Ltd.

Healthcare · Biotechnology

$2.22

Down-$0.07 (-3.15%)

Updated Oct 7, 2026, 10:28 PM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
150.12M
P/E ratio
-7.75
Dividend yield
0.00%
52-week range
$1.95 – $3.24
Volume
265.38K
Avg. volume
403.79K

Price performance · CGEN

CGEN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

CGEN closed at $2.22 after 21 trading sessions, down 13.28% for the selected period.

Last close
$2.22
Period change
-13.28%
Period low
$2.22
Period high
$2.56
Daily close
View OHLC price history
CGEN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$2.32$2.331$2.205$2.22265.38K
Oct 5, 2026$2.30$2.32$2.25$2.31198.87K
Oct 2, 2026$2.34$2.38$2.305$2.31113.99K
Oct 1, 2026$2.39$2.435$2.33$2.34173.35K
Sep 30, 2026$2.35$2.41$2.345$2.38118.24K
Sep 29, 2026$2.32$2.35$2.30$2.35117.18K
Sep 28, 2026$2.34$2.345$2.315$2.3394.07K
Sep 25, 2026$2.40$2.42$2.345$2.3877.76K
Sep 24, 2026$2.34$2.375$2.325$2.37111.36K
Sep 23, 2026$2.45$2.47$2.305$2.34288.33K
Sep 22, 2026$2.46$2.495$2.405$2.49230.98K
Sep 21, 2026$2.45$2.495$2.42$2.435217.39K
Sep 18, 2026$2.47$2.49$2.45$2.49128K
Sep 17, 2026$2.42$2.47$2.42$2.46122.76K
Sep 16, 2026$2.41$2.47$2.40$2.41117.64K
Sep 15, 2026$2.49$2.49$2.37$2.41330.76K
Sep 14, 2026$2.42$2.54$2.42$2.48144.47K
Sep 11, 2026$2.47$2.4961$2.43$2.47162.16K
Sep 10, 2026$2.48$2.51$2.44$2.46206.98K
Sep 9, 2026$2.55$2.55$2.46$2.48293.78K
Sep 8, 2026$2.55$2.625$2.55$2.56192.9K

Latest CGEN news

The latest Smart Investors Daily articles mentioning CGEN.

Stock researchCompany · Overview

CGEN research

Overview

Company profile and research snapshot.

Company profile

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$4.00
Implied upside
—
Analysts
—
CGEN recent ratings
DateFirmRatingTarget
May 21, 2026Leerink PartnersOutperform—
Apr 7, 2026Lake StreetBuy—
Jan 7, 2026HC Wainwright & Co.Buy—
May 21, 2024Truist SecuritiesBuy—
Mar 8, 2024Truist SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Compugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced it will host a virtual key opinion leader (KOL) event on Monday, October 5, 2026 at 8:00 AM ET featuring Oladapo Yeku, M.D., Ph.D., FACP (Harvard Medical School, Massachusetts General Hospital), who will join company management to discuss COM701 and the evolving treatment landscape in ovarian cancer. To register, click here.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By